Enzyme-therapy approaches for the treatment of drug overdose and addiction

Future Medicinal Chemistry

Volumn 3, Issue 1, 2011, Pages 9-13

  Zheng, Fang ^a   Zhan, Chang Guo ^a  

^a University of Kentucky   (United States)

Author keywords

drug abuse; drug addiction; drug metabolism; drug overdose; rational drug design; therapeutic enzyme

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABIS; COCAINE; DIAMORPHINE; METHAMPHETAMINE; METHCATHINONE; MORPHINE; OPIATE;

CENTRAL NERVOUS SYSTEM; DRUG DEPENDENCE; DRUG OVERDOSE; ENZYME THERAPY; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL;

BEHAVIOR, ADDICTIVE; COCAINE; DRUG DESIGN; ENZYME THERAPY; HUMANS; OVERDOSE; SUBSTANCE-RELATED DISORDERS;

EID: 78650635611     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.275     Document Type: Note

References (45)

1. Gorelick DA. Pharmacokinetic approaches to treatment of drug addiction. Expert Rev. Clin. Pharmacol. 1, 277-290 (2008).
2. Moreno AY, Janda HD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav. 92, 199-205 (2009).
3. Redish AD. Addiction as a computational process gone awry. Science 306, 1944-1947 (2004).
4. Novak G, Seeman P, Le Foll B. Exposure to nicotine produces an increase in dopamine D2(high) receptors: a possible mechanism for dopamine hypersensitivity. Int. J. Neurosci. 120, 691-697 (2010).
5. Novak M, Halbout B, OConnor EC et al. Incentive learning underlying cocaine-seeking requires mGluR5 receptors located on dopamine D1 receptor-expressing neurons. J. Neurosci. 30, 11973-11982 (2010).
6. Flatscher-Bader T, Wilce PA. The effect of alcohol and nicotine abuse on gene expression in the brain. Nutr. Res. Rev. 22, 148-162 (2009).
7. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 35, 217-238 (2010).
8. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr. Pharm. Des. 15, 2603-2614 (2009).
9. Huang X, Zhan CG. How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys. J. 93, 3627-3639 (2007).
10. Beuming T, Kniazeff J, Bergmann ML et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 11, 780-789 (2008).
11. Huang X, Gu H, Zhan CG. Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J. Phys. Chem. B. 113, 15057-15066 (2009).
12. Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. Expert Rev. Vaccines 9, 1109-1114 (2010).
13. Leader AE, Lerman C, Cappella JN. Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob. Res. 12, 390-397 (2010).
14. Moreno AY, Azar MR, Warren NA, Dickerson TJ, Koob GF, Janda KD. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol. Pharmcol. 7, 431-441 (2010).
15. Norman AB, Tabet MR, Norman MK, Tsibulsky VL. Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists. J. Neurosci. Methods DOI: 10.1016/j.jneumeth. 2010.10.017 (2010). (Epub ahead of print).
16. Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The fate and function of therapeutic anti-addiction monoclonal antibodies across the reproductive cycle of rats. J. Pharmacol. Exp. Ther. DOI: 10.1124/jpet.110. 175083 (2010). (Epub ahead of print).
17. Zhan CG, Zheng F, Landry DW. Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J. Am. Chem. Soc. 125, 2462-2474 (2003).
18. Landry DW, Zhao K, Yang GXQ, Glickman M, Georgiadis TM. Antibody catalyzed degradation of cocaine. Science 259, 1899-1901 (1993).
19. Yang W, Xue L, Fang L, Zhan CG. Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem. Biol. Interact. 187, 148-152 (2010).
20. Pan Y, Gao D, Yang W et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc. Natl Acad. Sci. USA 102, 16656-16661 (2005).
21. Pan Y, Gao D, Yang W, Cho H, Zhan CG. Free energy perturbation (FEP) simulation on the transition-states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J. Am. Chem. Soc. 129, 13537-13543 (2007).
22. Zheng F, Yang W, Ko MC et al. Most efficient cocaine hydrolase designed by virtual screening of transition States. J. Am. Chem. Soc. 130, 12148-12155 (2008).
23. Pan Y, Gao D, Zhan CG. Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J. Am. Chem. Soc. 130, 5140-5149 (2008).
24. Yang W, Pan Y, Zheng F, Cho H, Tai HH, Zhan CG. Free energy perturbation (FEP) simulation on transition states and design of high-activity mutants of human butyrylcholinesterase for accelerating cocaine metabolism. Biophysical J. 96, 1931-1938 (2009).
25. Yang W, Pan Y, Fang L, Gao D, Zheng F, Zhan CG. Free-energy perturbation simulation on transition states and high-activity mutants of human butyrylcholinesterase for (-)-cocaine hydrolysis. J. Phys. Chem. B 114, 10889-10896 (2010).
26. Zheng F, Yang W, Xue L, Hou S, Liu J, Zhan CG. Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency. Biochemistry 49, 9113-9119 (2010).
27. Gao D, Zhan CG. Modeling effects of oxyanion hole on the ester hydrolyses catalyzed by human cholinesterases. J. Phys. Chem. B 109, 23070-23076 (2005).
28. Gao D, Cho H, Yang W et al. Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew. Chem. Int. Ed. 45, 653-657 (2006).
29. Zhan CG, Gao D. Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine. Biophys. J. 89, 3863-3872 (2005).
30. Hamza A, Cho H, Tai HH, Zhan CG. Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J. Phys. Chem. B 109, 4776-4782 (2005).
31. Zhan CG. Modeling reaction mechanism of cocaine hydrolysis and rational drug design for therapeutic treatment of cocaine abuse. In: Topics in Heterocyclic Drugs (Volume 4). Gupta SP (Ed.). Springer-Verlag, Heidelberg, Germany, 107-159 (2006).
32. Cooper ZD, Narasimhan D, Sunahara RK et al. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol. 70, 1885-1891 (2006).
33. Ko MC, Bowen LD, Narasimhan D et al. Cocaine esterase: interactions with cocaine and immune responses in mice. J. Pharmacol. Exp. Ther. 320, 926-933 (2007).
34. Zheng F, Zhan CG. Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications. Future Med. Chem. 1, 515-528 (2009).
35. Zheng F, Zhan CG. Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose. Org. Biomol. Chem. 6, 836-843 (2008).
36. Zheng F, Zhan CG. Rational design of an enzyme mutant for anti-cocaine therapeutics. J. Comput. Aided Mol. Des. 22, 661-671 (2008).
37. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62, 220-224 (2002).
38. Xue L, Ko MC, Tong M et al. Design, preparation and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol. Pharmacol. DOI :10.1124/mol.110.068494 (2010). (Epub ahead of print).
39. Brimijoin S, Gao Y, Anker JJ. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33, 2715-2725 (2008).
40. Gao D, Narashihan DL, Macdonald J et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol. 75, 318-323 (2009).
41. Brim RL, Nance MR, Youngstrom DW. A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol. Pharmacol. 77, 593-600 (2010).
42. Collins GT, Brim RL, Narasimhan D et al. Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J. Pharm. Exp. Ther. 331, 445-455 (2009).
43. Narasimhan D, Nance MR, Gao D et al. Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng. Des. Sel. 23, 537-547 (2010).
44. Wood SK, Narasimhan D, Cooper Z et al. Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend. 106, 219-229 (2010).
45. Park JB, Kwon YM, Lee TY et al. PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J. Control. Release 2142, 174-179 (2010)